This invention relates generally to the diagnosis and treatment of electrophysiological diseases of the heart, and more specifically to devices and methods for epicardial mapping and ablation for the treatment of atrial fibrillation.
Atrial fibrillation results from disorganized electrical activity in the heart muscle, or myocardium. The surgical maze procedure has been developed for treating atrial fibrillation and involves the creation of a series of surgical incisions through the atrial myocardium in a preselected pattern so as to create conductive corridors of viable tissue bounded by scar tissue. While very effective in treating atrial fibrillation, the maze procedure is highly invasive, high in moribidity and mortality, and difficult to perform by even the most skilled surgeons. The procedure not only requires a median sternotomy or other form of gross thoracotomy for access to the heart, but requires stopping the heart and establishing cardiopulmonary bypass, to which a significant part of the trauma, morbidity and mortality of the maze procedure may be attributed.
As a less invasive alternative to the surgical incisions used in the maze procedure, transmural ablation of the heart wall has been proposed. Such ablation may be performed either from within the chambers of the heart (endocardial ablation) using endovascular devices (e.g. catheters) introduced through arteries or veins, or from outside the heart (epicardial ablation) using devices introduced into the chest through surgical incisions. Various ablation technologies have been proposed, including cryogenic, radiofrequency (RF), laser and microwave. The ablation devices are used to create elongated transmural lesions—that is, lesions extending through a sufficient thickness of the myocardium to block electrical conduction—which form the boundaries of the conductive corridors in the atrial myocardium. Perhaps most advantageous about the use of transmural ablation rather than surgical incisions is the ability to perform the procedure on the beating heart without the use of cardiopulmonary bypass.
In performing the maze procedure and its variants, whether using ablation or surgical incisions, it is generally considered most efficacious to include a transmural incision or lesion that isolates the pulmonary veins from the surrounding myocardium. The pulmonary veins connect the lungs to the left atrium of the heart, and join the left atrial wall on the posterior side of the heart. This location creates significant difficulties for endocardial ablation devices for several reasons. First, while many of the other lesions created in the maze procedure can be created from within the right atrium, the pulmonary venous lesions must be created in the left atrium, requiring either a separate arterial access point or a transeptal puncture from the right atrium. Second, the elongated and flexible endovascular ablation devices are difficult to manipulate into the complex geometries required for forming the pulmonary venous lesions and to maintain in such positions against the wall of the beating heart. This is very time-consuming and can result in lesions which do not completely encircle the pulmonary veins or which contain gaps and discontinuities. Third, visualization of endocardial anatomy and endovascular devices is often inadequate and knowing the precise position of such devices in the heart can be difficult, resulting in misplaced lesions. Fourth, ablation within the blood inside the heart can create thrombus which, in the right chambers, is generally filtered out by the lungs rather than entering the bloodstream. However, on the left side of the heart where the pulmonary venous lesions are formed, thrombus can be carried by the bloodstream into the coronary arteries or the vessels of the head and neck, potentially resulting in myocardial infarction, stroke or other neurologic sequelae. Finally, the heat generated by endocardial devices which flows outward through the myocardium cannot be precisely controlled and can damage extracardiac tissues such as the pericardium, the phrenic nerve and other structures.
If, on the other hand, epicardial ablation devices are utilized to form the pulmonary venous lesions, other challenges are presented. First, the posterior location of the pulmonary veins is extremely difficult to access through thoracic incisions without gross manipulations of the heart. Such manipulations are not generally possible if minimally-invasive techniques are being utilized via small thoracic access ports, or if the procedure is being performed on a beating heart without cardiopulmonary bypass. Further complicating epicardial access are the pericardial reflections, where the pericardium attaches to the heart wall near the pulmonary veins. The pericardial reflections are located so as to prohibit positioning a device completely around the pulmonary veins without cutting away or puncturing through the reflections. Such cutting or puncturing of the pericardial reflections is risky and difficult, particularly if working through small incisions in the chest without a clear view and open access to the posterior side of the heart. Furthermore, surgical repair of any damaged tissue is almost impossible without highly invasive open heart surgery.
What are needed, therefore, are devices and methods for forming transmural lesions that isolate the pulmonary veins from the surrounding myocardium which overcome these problems. The devices and methods will preferably be utilized epicardially to avoid the need for access into the left chambers of the heart and to minimize the risk of producing thrombus. The devices and methods should be useful through small access ports in the chest using minimally invasive techniques. The devices and methods will preferably avoid the need for cutting or puncturing the pericardial reflections, however, the pericardial reflections may be cut without departing from the scope of the invention. The devices and methods should further be useful on the beating heart without requiring the use of cardiopulmonary bypass and should not require significant manipulation or retraction of the heart.
The present invention meets these and other objectives by providing epicardial ablation devices and methods useful for creating transmural lesions that electrically isolate the pulmonary veins for the treatment of atrial fibrillation. The devices and methods may be utilized through a small access port in the chest, preferably through a subxiphoid penetration, and positioned within the pericardium and around the pulmonary veins. Advantageously, the devices and methods do not require the large thoracic incision used in the conventional maze procedure, and may be used on the beating heart without cardiopulmonary bypass. By eliminating the need for ablation within the left atrium, the risk of thrombus formation is minimized. The devices and methods of the invention are more easily visualized, faster to use, and more accurately positionable than known cardiac ablation catheters and devices, enable the formation of continuous, uninterrupted lesions around the pulmonary veins, and protect extracardiac tissues from injury.
In a first embodiment, a method of forming a transmural lesion in a wall of the heart adjacent to the pulmonary veins comprises the steps of placing at least one ablation device through a thoracic incision and through a pericardial penetration so that the at least one ablation device is disposed in contact with an epicardial surface of the heart wall; positioning the at least one ablation device adjacent to the pulmonary veins on a posterior aspect of the heart while leaving the pericardial reflections intact; and transmurally ablating the heart wall with the at least one ablating device to create at least one transmural lesion adjacent to the pulmonary veins. The ablation device is preferably placed through a small puncture, incision, or access port in the chest, either between the ribs or in a subxiphoid position, for minimal trauma, with visualization provided by fluoroscopy, endoscopy, transesophageal echocardiography, or other conventional form of minimally-invasive imaging. While the method may be performed with the heart stopped and circulation supported with cardiopulmonary bypass, the method is preferably performed with the heart beating so as to minimize morbidity, mortality, complexity and cost.
In another aspect of the invention, an apparatus for forming a transmural lesion in the heart wall adjacent to the pulmonary veins comprises, in a preferred embodiment, an elongated flexible shaft having a working end and a control end; an ablation device attached to the working end for creating a transmural lesion in the heart wall; a control mechanism at the control end for manipulating the working end; and a locating device near the working end configured to engage one or more of the pulmonary veins, or a nearby anatomical structure such as a pericardial reflection, for positioning the working end adjacent to the pulmonary veins. The locating device may comprise a catch, branch, notch or other structure at the working end configured to engage one or more of the pulmonary veins or other anatomical structure such as the inferior vena cava, superior vena cava, aorta, pulmonary artery, left atrial appendage, right atrial appendage, or one of the pericardial reflections. The ablation device may be a radiofrequency electrode, microwave transmitter, cryogenic element, laser, ultrasonic transducer or any of the other known types of ablation devices suitable for forming transmural lesions. Preferably, the apparatus includes a plurality of such ablation devices arranged along the working end in a linear pattern suitable for forming a continuous, uninterrupted lesion around or on the pulmonary veins.
The working end may additionally include one or more movable elements that are manipulated from the control end and which may be moved into a desired position after the working end has been located near the pulmonary veins. Slidable, rotatable, articulated, pivotable, bendable, pre-shaped or steerable elements may be used. Additional ablation devices may be mounted to these movable elements to facilitate formation of transmural lesions. The movable elements may be deployed to positions around the pulmonary veins to create a continuous transmural lesion which electrically isolates the pulmonary veins from the surrounding myocardium.
In addition, a mechanism may be provided for urging all or part of the working end against the epicardium to ensure adequate contact with the ablation devices. This mechanism may be, for example, one or more suction holes in the working end through which suction may be applied to draw the working end against the epicardium, or an inflatable balloon mounted to the outer side of the working end such that, upon inflation, the balloon engages the inner wall of the pericardium and forces the working end against the epicardium. This also functions to protect extracardiac tissues such as the pericardium from injury by retracting such tissues away from the epicardial region which is being ablated, and, in the case of the balloon, providing an insulated barrier between the electrodes of the ablation probe and the extracardiac tissues.
The apparatus may be either a single integrated device or two or more devices which work in tandem. In either case, the apparatus may have two or more tips at the working end which are positioned on opposing sides of a tissue layer such as a pericardial reflection. A device may be provided for approximating the two free ends on opposing sides of the tissue layer, such as an electromagnet mounted to one or both of the free ends. In this way, a continuous lesion may be created in the myocardium from one side of the pericardial reflection to the other without puncturing or cutting away the pericardial reflection.
The apparatus may further include a working channel through which supplemental devices may be placed to facilitate visualization, tissue manipulation, supplementary ablation, suction, irrigation and the like.
The apparatus and methods of the invention are further useful for mapping conduction pathways in the heart (local electrograms) for the diagnosis of electrophysiological diseases. Any of the electrodes on the apparatus may be individually selected and the voltage may be monitored to determine the location of conduction pathways. Alternatively, the apparatus of the invention may be used for pacing the heart by delivering current through one or more selected electrodes at levels sufficient to stimulate heart contractions.
Additionally, although the ablation apparatus and methods of the invention are preferably configured for epicardial use, the principles of the invention are equally applicable to endocardial ablation catheters and devices. For example, an endocardial ablation apparatus according to the invention would include a locating device configured to engage an anatomical structure accessible from within the chambers of the heart such as the coronary sinus (from the right atrium), pulmonary artery (from the right ventricle), or the pulmonary veins (from the left atrium), and the ablation device would be positionable in a predetermined location relative to the locating device. The endocardial apparatus could further include suction holes, expandable balloons, or other mechanisms for maintaining contact between the ablation device and the interior surface of the heart wall.
In another aspect of the present invention, an anchor is used to hold a part of the device while displacing another part of the device. The anchor is preferably a balloon but may also be tines, a suction port or a mechanically actuated device. After actuating the anchor, a proximal portion of the device may be moved by simply manipulating the device or by advancement or withdrawal of a stylet.
The present invention is also related to a method of creating a continuous ablation lesion in tissue underlying a pericardial reflection without penetrating the pericardial reflection. First and second ablating devices are introduced into the space between the pericardium and the epicardium. The first ablating device is positioned on one side of the pericardial reflection and the second ablating device is positioned on the other side of the pericardial reflection. Tissue beneath the pericardial reflection is then ablated with one or both of the devices to create a continuous lesion beneath the pericardial reflection. The devices may be aligned across the pericardial reflection by any suitable method such as with magnetic force, use of an emitter and sensor, or by marking the pericardial reflection on one side and locating the mark from the other side of the pericardial reflection. The emitter and sensor may work with electromagnetic radiation such as light, ultrasound, magnetic field, and radiation.
In yet another aspect of the invention, the ablating device may have a guide portion which aligns the device between the pericardium and epicardium. The guide portion may be a continuous strap or a number of discrete guide portions. The guide portions may be fins, wings or one or more laterally extending elements such as balloons. The guide portions may be individually actuated to align the device and ablate discrete locations of the tissue along the ablating device.
The ablating device may also be advanced into position over a guide. The guide is preferably a guidewire but may be any other suitable structure. The guide may also lock into position with a coaxial cable or locking arm. The guide is advanced ahead of the ablation device and positioned along the desired ablation path. The ablating device is then advanced or retracted along the guide. The ablating device preferably includes a device for locating previously formed lesions so that subsequent lesions will merge with previously formed lesion to create a continuous, transmural lesion. The device for locating previously created lesions may be pacing and sensing electrodes or electrodes which simply measure electrical impedance.
Although cutting through the pericardial reflections has certain risks, the methods and devices of the present invention may, of course, be practiced while cutting through the pericardial reflections. After penetrating through the pericardial reflection, the ablating device may interlock with another part of the same device or with a separate device.
Other aspects and advantages of the invention are disclosed in the following detailed description and in the accompanying drawings.
Working end 24 includes a plurality of ablating elements 27. The ablating elements 27 are preferably a plurality of electrodes 28 for delivering radiofrequency (RF) current to the myocardium so as to create transmural lesions of sufficient depth to block electrical conduction. Electrodes 28 may be partially-insulated solid metal rings or cylinders, foil strips, wire coils or other suitable construction for producing elongated lesions. Electrodes 28 are spaced apart a distance selected so that the lesions created by adjacent electrodes contact or overlap one another, thereby creating a continuous, uninterrupted lesion in the tissue underlying the electrodes. In an exemplary embodiment, electrodes 28 are about 2-20 mm in length and are spaced apart a range of 1-6 mm. It is understood that the term electrodes 28 as used herein may refer to any suitable ablating element 27. For example, as an alternative to RF electrodes, the ablating elements 27 may be microwave transmitters, cryogenic element, laser, heated element, ultrasound, hot fluid or other types of ablation devices suitable for forming transmural lesions. The heated element may be a self-regulating heater to prevent overheating. Electrodes 28 are positioned so as to facilitate lesion formation on the three-dimensional topography of the left atrium. For example, lateral electrodes 28a face medially to permit ablation of the myocardium on the lateral side of the left inferior pulmonary vein and medial electrodes 28b face anteriorly to permit ablation of the posterior surface of the myocardium adjacent to the left inferior pulmonary vein.
Working end 24 further includes a locating mechanism which locates the working end at one of the pulmonary veins and helps to maintain it in position once located. In a preferred embodiment, working end 24 is bifurcated into two branches 30, 32, and the locating mechanism is a notch 34 disposed between the two branches. Notch 34 tapers into a concave surface 36 so as to receive one of the pulmonary veins between branches 30, 32 and to atraumatically engage the pulmonary vein against concave surface 36. In an exemplary embodiment, notch 34 is about 10 to 30 mm in width at its widest point between branches 30, 32 and tapers toward concave surface 36 which has a radius of curvature of about 4 to 15 mm, so as to conform to the outer curvature of the pulmonary vein. Preferably, notch 34 is sized and positioned for placement against the left inferior pulmonary vein, as described more fully below. Alternatively, the locating mechanism may be configured to engage another anatomic structure such as the inferior vena cava, superior vena cava, pericardial reflections, pulmonary vein, aorta, pulmonary artery, atrial appendage, or other structure in the space between the pericardium and the myocardium. The various shapes of the ablating devices described and shown herein are, of course, useful in locating various structures to position the ablating elements against predetermined tissues to be ablated.
Working end 24 further includes a superior sub-probe 38 and an inferior sub-probe 40 which are slidably extendable from working end 24, as further described below.
Control end 26 includes a handle 42 and a plurality of slidable actuators 44A-44E, which are used to extend superior sub-probe 38 and inferior sub-probe 40 from working end 24, and to perform other functions as described below. An electrical connector 46 suitable for connection to an RF generator is mounted to handle 42 and is electrically coupled to electrodes 28 at working end 24. Also mounted to handle 42 are a working port 48 in communication with a working channel 92, described below, and a connector 50 for connection to a source of inflation fluid or suction, used for purposes described below.
Right ablation probe 22 has a flexible shaft 52 extending from a control end 54 to a working end 56. Working end 56 has a cross-member 58 to which are mounted a plurality of electrodes 60. Cross member 58 preferably has tips 59 which are pre-shaped or deflectable into a curve so as to conform to the right lateral walls of the right pulmonary veins, and which are separated by a distance selected so that the two right pulmonary veins may be positioned between them, usually a distance of about 20-50 mm. Electrodes 60 are sized and positioned so as to create a continuous lesion along the right side (from the patient's perspective) of the pulmonary veins as described more fully below. In an exemplary embodiment, electrodes 60 are about 2-20 mm in length, and are spaced apart about 1-6 mm. Shaft 52 is dimensioned to allow introduction through a small incision in the chest, preferably in a subxiphoid location, and advanced to the pulmonary veins on the posterior side of the heart. Shaft 52 will have dimensions, geometry and materials like those of shaft 21 of left ablation probe 20, described above.
Control end 54 includes a handle 62. An electrical connector 64 adapted for connection to an RF generator is attached to handle 62 and is electrically coupled to electrodes 60 at working end 56. An inflation or suction connector 65 is mounted to handle 62 and adapted for connection to a source of inflation fluid or suction, for purposed described below. Handle 62 may further include a working port (not shown) like working port 48 described above in connection with left ablation probe 20.
As shown in
Referring to
Referring to
The distal end of inner probe 74 has a tip electrode 104 for extending the transmural lesion produced by electrodes 76. Preferably, inner probe 74 further includes a device for approximating the tip of inner probe 74 with the superior tip 106 of right ablation probe 22 (
It should be noted that thermocouples, thermistors or other temperature monitoring devices may be mounted to the working ends of either left or right ablation probes 20, 22 to facilitate temperature measurement of the epicardium during ablation. The thermocouples may be mounted adjacent to any of the electrodes described above, or may be welded or bonded to the electrodes themselves. The thermocouples will be coupled to wires which extend through shafts 21, 52 alongside the electrode wires to connectors 46, 64 or to separate connectors on handles 42, 62, facilitating connection to a temperature monitoring device.
Referring to
Actuators 44A-C are slidably disposed in a longitudinal slot 136 in handle 42, as more clearly shown in
The slidable relationship between the shafts and probes 74, 40, 38 helps to guide and direct the probes to the tissues to be ablated. The shafts have various features, including the ablating elements 27, however, the shafts may be simple sheaths which locate structures and/or direct the probes into various regions of the pericardial space.
Referring now to
A subxiphoid incision (inferior to the xiphoid process of the sternum) is made about 2-5 cm in length. Under direct vision through such incision or by visualization with an endoscope, a second small incision is made in the pericardium P (
Superior sub-probe 38 is then advanced distally from working end 24 until its steerable section 68 is beyond the superior side of the left superior pulmonary vein LS. Steerable section 68 is then deflected into the curved configuration shown in
Inferior sub-probe 40 is next advanced from working end 24 while maintaining tension on tether 80 such that the inferior sub-probe engages and conforms to the shape of the pericardial reflection PR between the left inferior and right inferior pulmonary veins. When inferior sub-probe 40 has been fully advanced, tension is released on tether 80 so that distal tip 78 moves superiorly into engagement with the right inferior pulmonary vein RI adjacent to pericardial reflection PR inferior thereto.
Right ablation probe 22 is placed through the subxiphoid incision and pericardial incision and advanced around the right side of the heart as shown in
It should be noted that the pericardium P attaches to the heart at the pericardial reflections PR shown in
RF generator 140 is then activated to deliver RF energy to electrodes 28, 60, 66, 76, 82, 104, and 112 on left and right ablation probes 20, 22, producing the transmural lesion L shown in
Ablation probes 20, 22 may further be used for mapping conduction pathways in the heart (local electrocardiograms) for the diagnosis of electrophysiological abnormalities. This is accomplished by selecting any of the electrodes on the ablation probes and monitoring the voltage. A commercially available electrophysiology monitoring system is utilized, which can select any electrode on the ablation probes and monitor the voltage. Various electrodes and various locations on the heart wall may be selected to develop a map of potential conduction pathways in the heart wall. If ablation treatment is then required, the steps outlined above may be performed to create transmural lesions at the desired epicardial locations.
During any of the preceding steps, devices may be placed through working port 142 and working channel 92 to assist and supplement the procedure. For example, a flexible endoscope may be introduced for visualization to assist positioning. Ultrasound probes may be introduced to enhance visualization and for measuring the location and/or depth of transmural lesions. Suction or irrigation devices may be introduced to clear the field and remove fluid and debris. Tissue manipulation and retraction devices may be introduced to move and hold tissue out of the way. Cardiac mapping and ablation devices may also be introduced to identify conduction pathways and to supplement the ablation performed by left and right ablation probes 20, 22.
Furthermore, mapping and ablation catheters, temperature monitoring catheters, and other endovascular devices may be used in conjunction with the left and right ablation probes of the invention by introducing such devices into the right atrium or left atrium either through the arterial system or through the venous system via the right atrium and a transeptal puncture. For example, an ablation catheter may be introduced into the left atrium to ablate any region of the myocardium not sufficiently ablated by left and right ablation probes 20, 22 in order to ensure complete isolation of the pulmonary veins. Additionally, ablation catheters may be introduced into the right chambers of the heart, or epicardial ablation devices may be introduced through incisions in the chest, to create other transmural lesions.
In some cases, it may be desirable to actively ensure adequate contact between the epicardium and the electrodes of left and right ablation probes 20, 22. For this purpose, left ablation probe 20 and/or right ablation probe 22 may include one or more expandable devices such as balloons which are inflated in the space between the heart and the pericardium to urge the ablation probe against the epicardial surface. An exemplary embodiment is shown in
Alternatively or additionally, suction ports may be provided in the ablation probes of the invention to draw the electrodes against the epicardium, as shown in
Referring to
Referring to
Referring to
The ablating device 20A also has an anchor 170 to anchor a portion of the device 20A while moving another part of the device 20A. When the anchor 170 is the balloon 150, the balloon may have a number of chambers 171, preferably three, which can be inflated as necessary to position the device as shown in
Referring to
The ablating device 20A, like the ablating device 20, may also have a portion 176 which is moved to ablate tissue inferior to the left and right inferior pulmonary veins. Stated another way, the portion 176 is moved to a position inferior to the inferior pulmonary veins. The portion 176 is moved into the position shown in
Still referring to
The ablating device 20A, 22A are also similar to the ablating devices 20, 22 in that the ablating devices 20A, 22A create continuous lesions on both sides of the pericardial reflections extending between the vena cava and the right superior and right inferior pulmonary veins. Tissue beneath the pericardial reflections is ablated using at least one of the ablating devices 20A, 22A. The ablating devices 20A, 22A may be approximated using any suitable technique or device such as with magnetic force described above. Other methods and devices for creating a continuous lesion beneath a pericardial reflection are described below.
Referring now to
Yet another method to make sure that the ablating devices 20A, 22A are aligned across a pericardial reflection is to mark a location on the pericardial reflection where a lesion has been created as shown in
Referring again to
Referring now to
Referring to
The expanding elements 192 may also be inflated at selected locations corresponding to discrete ablation sites as shown in
Another ablating device 20D is now described with reference to
The ablating device 20D and/or the guide 200 preferably includes a device 206 for aligning the ablating element with a previously created lesion. The aligning device 206 may be electrodes 191, 193 which simply measure electrical impedance. When the electrodes 191, 193 measure a large increase in electrical impedance an ablation is positioned beneath the electrodes 191, 193. In this manner, the ablating element 27 can be aligned and positioned to create a continuous lesion through the tissue. Referring to
Still referring to
The electrodes 194, 196 may also be used to locate the end of a previously created lesion. The time between emission of the pacing stimulus to receipt of the cardiac impulse at the sensing electrode increases when a transmural ablation has been created between the electrodes 194, 196. When such an increase is detected, it is known that the previously created lesion is positioned between the electrodes 194, 196. The time between emission and receipt of the cardiac impulse may also be used in simple time of flight analysis to determine the location of a discontinuity in the ablation. For example, the electrodes 194, 196 are positioned at a discontinuity in an ablation when the time of flight is lowest.
A method of using the device is shown in
Referring to
The expandable device 209 is mounted to a body 211 having a scalloped appearance to provide flexibility although any other suitable design may be used. The body 211 has a C-shaped cross-section which engages a flange 221 on the ablating device 210. The expandable device 209 is preferably the balloon 150A but may be a mechanically actuated device. For example, the expandable device 209 can be an extendable arm, a wire loop or an expandable mesh. The anchor 170 may be selectively expandable to guide, rotate, and move the ablating device 210 as necessary. The balloon 150A preferably has at least two separately inflatable chambers 212 and
As mentioned above, penetrating the pericardial reflections carries inherent risks. However, the methods and devices of the invention may, of course, be used when penetrating the pericardial reflections. The ablating devices 20, 22, 20A, 22A may have a penetrating element 220 as shown in
Referring to
Referring to
While the above is a complete description of the preferred embodiments of the invention, various alternatives, substitutions and modifications may be made without departing from the scope thereof, which is defined by the following claims. For example, any of the ablating devices described herein may have the anchor, fins, lateral balloons, sensors, and/or electrodes without departing from the scope of the invention.
This application is a continuation of application Ser. No. 10/232,963, filed on Aug. 30, 2002, now U.S. Pat. No. 6,949,095, which is a continuation of application Ser. No. 09/440,823, filed Nov. 15, 1999, now U.S. Pat. No. 6,484,727, which is a continuation of application Ser. No. 09/356,476, filed Jul. 19, 1999, now U.S. Pat. No. 6,311,692, which is a continuation-in-part of application Ser. No. 09/157,824, filed Sep. 21, 1998, now U.S. Pat. No. 6,237,605, which is a continuation-in-part of application Ser. No. 08/943,683, filed Oct. 15, 1997, now U.S. Pat. No. 6,161,543, which is a continuation-in-part of application Ser. No. 08/735,036, filed Oct. 22, 1996, now abandoned, the complete disclosures of which are incorporated herein by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
984756 | Frisch | Feb 1911 | A |
3369550 | Armao et al. | Feb 1968 | A |
3862627 | Hans, Sr. | Jan 1975 | A |
4022215 | Benson | May 1977 | A |
4072152 | Linehan | Feb 1978 | A |
4207874 | Choy | Jun 1980 | A |
4353371 | Cosman | Oct 1982 | A |
4375818 | Suwaki et al. | Mar 1983 | A |
4655216 | Tischer | Apr 1987 | A |
4736749 | Lundback | Apr 1988 | A |
4786155 | Fantone et al. | Nov 1988 | A |
4802475 | Weshahy | Feb 1989 | A |
4815470 | Curtis et al. | Mar 1989 | A |
4836191 | Noske et al. | Jun 1989 | A |
4872346 | Kelly-Fry et al. | Oct 1989 | A |
4889137 | Kolobow | Dec 1989 | A |
4917095 | Fry et al. | Apr 1990 | A |
4924863 | Sterzer | May 1990 | A |
4936281 | Stasz | Jun 1990 | A |
4957099 | Hassler | Sep 1990 | A |
4976711 | Parins et al. | Dec 1990 | A |
4985030 | Melzer et al. | Jan 1991 | A |
5000185 | Yock | Mar 1991 | A |
5013312 | Parins et al. | May 1991 | A |
5080102 | Dory | Jan 1992 | A |
5108390 | Potocky et al. | Apr 1992 | A |
5109830 | Cho | May 1992 | A |
5147355 | Friedman et al. | Sep 1992 | A |
5190541 | Abele et al. | Mar 1993 | A |
5197964 | Parins | Mar 1993 | A |
5222501 | Ideker et al. | Jun 1993 | A |
5224943 | Goddard | Jul 1993 | A |
5231995 | Desai | Aug 1993 | A |
5254116 | Baust et al. | Oct 1993 | A |
5263493 | Avitall | Nov 1993 | A |
5269291 | Carter | Dec 1993 | A |
5277201 | Stern | Jan 1994 | A |
5281215 | Milder | Jan 1994 | A |
5290286 | Parins | Mar 1994 | A |
5295484 | Marcus et al. | Mar 1994 | A |
5323781 | Ideker et al. | Jun 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5324284 | Imran | Jun 1994 | A |
5334181 | Rubinsky et al. | Aug 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5348554 | Imran et al. | Sep 1994 | A |
5353783 | Nakao et al. | Oct 1994 | A |
5354258 | Dory | Oct 1994 | A |
5366443 | Eggers et al. | Nov 1994 | A |
5370675 | Edwards et al. | Dec 1994 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5396887 | Imran | Mar 1995 | A |
5400783 | Pomeranz et al. | Mar 1995 | A |
5405376 | Mulier et al. | Apr 1995 | A |
5406946 | Imran | Apr 1995 | A |
5409483 | Campbell et al. | Apr 1995 | A |
5423807 | Milder | Jun 1995 | A |
5423811 | Imran et al. | Jun 1995 | A |
5427119 | Swartz et al. | Jun 1995 | A |
5431649 | Mulier et al. | Jul 1995 | A |
5433708 | Nichols et al. | Jul 1995 | A |
5435308 | Gallup et al. | Jul 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5437664 | Cohen et al. | Aug 1995 | A |
5443463 | Stern et al. | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5450843 | Moll et al. | Sep 1995 | A |
5452733 | Sterman et al. | Sep 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5462545 | Wang et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5469853 | Law et al. | Nov 1995 | A |
5478330 | Imran et al. | Dec 1995 | A |
5487385 | Avitall | Jan 1996 | A |
5487757 | Truckai et al. | Jan 1996 | A |
5496312 | Klicek | Mar 1996 | A |
5497774 | Swartz et al. | Mar 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5501655 | Rolt et al. | Mar 1996 | A |
5501698 | Roth et al. | Mar 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5520682 | Baust et al. | May 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5540679 | Fram et al. | Jul 1996 | A |
5540681 | Strul et al. | Jul 1996 | A |
5545195 | Lennox et al. | Aug 1996 | A |
5545200 | West et al. | Aug 1996 | A |
5549661 | Kordis et al. | Aug 1996 | A |
5555883 | Avitall | Sep 1996 | A |
5558644 | Boyd et al. | Sep 1996 | A |
5560362 | Sliwa, Jr. et al. | Oct 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5569241 | Edwards | Oct 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5575766 | Swartz et al. | Nov 1996 | A |
5575788 | Baker et al. | Nov 1996 | A |
5575810 | Swanson et al. | Nov 1996 | A |
5578007 | Imran | Nov 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5590657 | Cain et al. | Jan 1997 | A |
5595183 | Swanson et al. | Jan 1997 | A |
5607462 | Imran | Mar 1997 | A |
5617854 | Munsif | Apr 1997 | A |
5626607 | Malecki et al. | May 1997 | A |
5630837 | Crowley | May 1997 | A |
5637090 | McGee et al. | Jun 1997 | A |
5643197 | Brucker et al. | Jul 1997 | A |
5656029 | Imran et al. | Aug 1997 | A |
5658278 | Imran et al. | Aug 1997 | A |
5671747 | Connor | Sep 1997 | A |
5673695 | McGee et al. | Oct 1997 | A |
5676662 | Fleischhacker et al. | Oct 1997 | A |
5676692 | Sanghvi et al. | Oct 1997 | A |
5676693 | LaFontaine | Oct 1997 | A |
5678550 | Bassen et al. | Oct 1997 | A |
5680860 | Imran | Oct 1997 | A |
5681278 | Igo et al. | Oct 1997 | A |
5681308 | Edwards et al. | Oct 1997 | A |
5687723 | Avitall | Nov 1997 | A |
5687737 | Branham et al. | Nov 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5690611 | Swartz et al. | Nov 1997 | A |
5697925 | Taylor | Dec 1997 | A |
5697927 | Imran et al. | Dec 1997 | A |
5697928 | Walcott et al. | Dec 1997 | A |
5697949 | Giurtino et al. | Dec 1997 | A |
5713942 | Stern | Feb 1998 | A |
5716389 | Walinsky et al. | Feb 1998 | A |
5718241 | Ben-Haim et al. | Feb 1998 | A |
5718701 | Shai et al. | Feb 1998 | A |
5720775 | Lanard | Feb 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5728094 | Edwards et al. | Mar 1998 | A |
5730074 | Peter | Mar 1998 | A |
5730127 | Avitall | Mar 1998 | A |
5730704 | Avitall | Mar 1998 | A |
5733280 | Avitall | Mar 1998 | A |
5735280 | Sherman et al. | Apr 1998 | A |
5735290 | Sterman et al. | Apr 1998 | A |
5746224 | Edwards | May 1998 | A |
5755760 | Maguire et al. | May 1998 | A |
5776176 | Rudie | Jul 1998 | A |
5782828 | Chen et al. | Jul 1998 | A |
5782899 | Imran | Jul 1998 | A |
5785706 | Bednarek | Jul 1998 | A |
5788636 | Curley | Aug 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5800428 | Nelson et al. | Sep 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5800484 | Gough et al. | Sep 1998 | A |
5810721 | Mueller et al. | Sep 1998 | A |
5810802 | Panescu et al. | Sep 1998 | A |
5817021 | Reichenberger | Oct 1998 | A |
5823197 | Edwards | Oct 1998 | A |
5827216 | Igo et al. | Oct 1998 | A |
5827281 | Levin | Oct 1998 | A |
5830214 | Flom et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5840030 | Ferek-Petric et al. | Nov 1998 | A |
5844349 | Oakley et al. | Dec 1998 | A |
5846218 | Brisken et al. | Dec 1998 | A |
5849028 | Chen | Dec 1998 | A |
5860951 | Eggers et al. | Jan 1999 | A |
5861021 | Thome et al. | Jan 1999 | A |
5863291 | Schaer | Jan 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5871525 | Edwards et al. | Feb 1999 | A |
5873845 | Cline et al. | Feb 1999 | A |
5876399 | Chia et al. | Mar 1999 | A |
5879295 | Li et al. | Mar 1999 | A |
5879296 | Ockuly et al. | Mar 1999 | A |
5882346 | Pomeranz et al. | Mar 1999 | A |
5885278 | Fleischman | Mar 1999 | A |
5891134 | Gobe et al. | Apr 1999 | A |
5893848 | Negus et al. | Apr 1999 | A |
5895417 | Pomeranz et al. | Apr 1999 | A |
5897554 | Chia et al. | Apr 1999 | A |
5899898 | Arless et al. | May 1999 | A |
5899899 | Arless et al. | May 1999 | A |
5902289 | Swartz et al. | May 1999 | A |
5904711 | Flom et al. | May 1999 | A |
5906580 | Kline-Schoder et al. | May 1999 | A |
5916213 | Haissaguerre et al. | Jun 1999 | A |
5916214 | Cosio et al. | Jun 1999 | A |
5921924 | Avitall | Jul 1999 | A |
5921982 | Lesh et al. | Jul 1999 | A |
5927284 | Borst et al. | Jul 1999 | A |
5928191 | Houser et al. | Jul 1999 | A |
5931810 | Grabek | Aug 1999 | A |
5931848 | Saadat | Aug 1999 | A |
5954661 | Greenspon et al. | Sep 1999 | A |
5971980 | Sherman | Oct 1999 | A |
5971983 | Lesh | Oct 1999 | A |
5993447 | Blewett et al. | Nov 1999 | A |
6007499 | Martin et al. | Dec 1999 | A |
6012457 | Lesh | Jan 2000 | A |
6016811 | Knopp et al. | Jan 2000 | A |
6023638 | Swanson | Feb 2000 | A |
6042556 | Beach et al. | Mar 2000 | A |
6048329 | Thompson et al. | Apr 2000 | A |
6068629 | Haissaguerre et al. | May 2000 | A |
6071274 | Thompson et al. | Jun 2000 | A |
6071279 | Whayne et al. | Jun 2000 | A |
6071282 | Fleischman | Jun 2000 | A |
6088894 | Oakley | Jul 2000 | A |
6113592 | Taylor | Sep 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6120496 | Whayne et al. | Sep 2000 | A |
6120500 | Bednarek et al. | Sep 2000 | A |
6139563 | Cosgrove et al. | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6142994 | Swanson et al. | Nov 2000 | A |
6146379 | Fleischman et al. | Nov 2000 | A |
6152920 | Thompson et al. | Nov 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6212426 | Swanson | Apr 2001 | B1 |
6214754 | Stein | Apr 2001 | B1 |
6217528 | Koblish et al. | Apr 2001 | B1 |
6217576 | Tu et al. | Apr 2001 | B1 |
6231518 | Grabek et al. | May 2001 | B1 |
6235024 | Tu | May 2001 | B1 |
6237605 | Vaska et al. | May 2001 | B1 |
6238347 | Nix et al. | May 2001 | B1 |
6241722 | Dobak et al. | Jun 2001 | B1 |
6241727 | Tu et al. | Jun 2001 | B1 |
6245061 | Panescu et al. | Jun 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6270471 | Hechel et al. | Aug 2001 | B1 |
6270476 | Santoianni et al. | Aug 2001 | B1 |
6293943 | Panescu et al. | Sep 2001 | B1 |
6296619 | Brisken et al. | Oct 2001 | B1 |
6302880 | Schaer | Oct 2001 | B1 |
6308091 | Avitall | Oct 2001 | B1 |
6311692 | Vaska et al. | Nov 2001 | B1 |
6312383 | Lizzi et al. | Nov 2001 | B1 |
6314962 | Vaska et al. | Nov 2001 | B1 |
6314963 | Vaska et al. | Nov 2001 | B1 |
6325797 | Stewart et al. | Dec 2001 | B1 |
6325798 | Edwards et al. | Dec 2001 | B1 |
6332881 | Carner et al. | Dec 2001 | B1 |
6361531 | Hissong | Mar 2002 | B1 |
6364876 | Erb et al. | Apr 2002 | B1 |
6368275 | Sliwa et al. | Apr 2002 | B1 |
6371955 | Fuimaono et al. | Apr 2002 | B1 |
6383151 | Diederich et al. | May 2002 | B1 |
6385472 | Hall et al. | May 2002 | B1 |
6398792 | O'Connor | Jun 2002 | B1 |
6409720 | Hissong et al. | Jun 2002 | B1 |
6413254 | Hissong et al. | Jul 2002 | B1 |
6419648 | Vitek et al. | Jul 2002 | B1 |
6425867 | Vaezy et al. | Jul 2002 | B1 |
6430426 | Avitall | Aug 2002 | B2 |
6447507 | Bednarek et al. | Sep 2002 | B1 |
6454758 | Thompson et al. | Sep 2002 | B1 |
6461314 | Pant et al. | Oct 2002 | B1 |
6461356 | Patterson | Oct 2002 | B1 |
6464700 | Koblish et al. | Oct 2002 | B1 |
6471697 | Lesh | Oct 2002 | B1 |
6471698 | Edwards et al. | Oct 2002 | B1 |
6474340 | Vaska et al. | Nov 2002 | B1 |
6477396 | Mest et al. | Nov 2002 | B1 |
6484727 | Vaska et al. | Nov 2002 | B1 |
6500174 | Maguire et al. | Dec 2002 | B1 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6517536 | Hooven et al. | Feb 2003 | B2 |
6527767 | Wang et al. | Mar 2003 | B2 |
6527769 | Langberg et al. | Mar 2003 | B2 |
6544262 | Fleischman | Apr 2003 | B2 |
6546934 | Ingle et al. | Apr 2003 | B1 |
6582423 | Thapliyal et al. | Jun 2003 | B1 |
6605084 | Acker et al. | Aug 2003 | B2 |
6610055 | Swanson et al. | Aug 2003 | B1 |
6645199 | Jenkins et al. | Nov 2003 | B1 |
6645202 | Pless et al. | Nov 2003 | B1 |
6689128 | Sliwa et al. | Feb 2004 | B2 |
6692450 | Coleman | Feb 2004 | B1 |
6701931 | Sliwa et al. | Mar 2004 | B2 |
6740080 | Jain et al. | May 2004 | B2 |
6745080 | Koblish | Jun 2004 | B2 |
6767346 | Damasco et al. | Jul 2004 | B2 |
6771996 | Bowe et al. | Aug 2004 | B2 |
6805128 | Pless et al. | Oct 2004 | B1 |
6805129 | Pless et al. | Oct 2004 | B1 |
6840936 | Sliwa et al. | Jan 2005 | B2 |
6858026 | Sliwa et al. | Feb 2005 | B2 |
6942661 | Swanson | Sep 2005 | B2 |
6942662 | Goble et al. | Sep 2005 | B2 |
7052493 | Vaska et al. | May 2006 | B2 |
7213601 | Stevens et al. | May 2007 | B2 |
7338486 | Sliwa et al. | Mar 2008 | B2 |
7387126 | Cox et al. | Jun 2008 | B2 |
7517345 | Cox et al. | Apr 2009 | B2 |
7674257 | Pless et al. | Mar 2010 | B2 |
7955325 | Wittenberger et al. | Jun 2011 | B2 |
20020013579 | Silvestrini | Jan 2002 | A1 |
20020019627 | Maguire et al. | Feb 2002 | A1 |
20020022839 | Stewart et al. | Feb 2002 | A1 |
20020026183 | Simpson | Feb 2002 | A1 |
20020042010 | Lin | Apr 2002 | A1 |
20020062124 | Keane | May 2002 | A1 |
20020087151 | Mody et al. | Jul 2002 | A1 |
20020087208 | Koblish et al. | Jul 2002 | A1 |
20020111567 | Vanden Hoek et al. | Aug 2002 | A1 |
20020128639 | Pless et al. | Sep 2002 | A1 |
20020143326 | Foley et al. | Oct 2002 | A1 |
20030078571 | Sliwa, Jr. et al. | Apr 2003 | A1 |
20040106918 | Cox et al. | Jun 2004 | A1 |
20040260278 | Anderson et al. | Dec 2004 | A1 |
20050033274 | Pless et al. | Feb 2005 | A1 |
20050245918 | Sliwa, Jr. et al. | Nov 2005 | A1 |
20050251125 | Pless et al. | Nov 2005 | A1 |
20060135954 | Sliwa, Jr. et al. | Jun 2006 | A1 |
20060184167 | Vaska et al. | Aug 2006 | A1 |
20060200119 | Vaska et al. | Sep 2006 | A1 |
20070066974 | Vaska et al. | Mar 2007 | A1 |
20070293855 | Sliwa et al. | Dec 2007 | A1 |
20070299496 | Podmore et al. | Dec 2007 | A1 |
20080045946 | Vaska | Feb 2008 | A1 |
20090192603 | Ryan | Jul 2009 | A1 |
Number | Date | Country |
---|---|---|
A-7052296 | Nov 1994 | AU |
1181896 | Feb 2002 | EP |
2 094 636 | Sep 1982 | GB |
2 289 510 | Nov 1995 | GB |
WO 9510318 | Apr 1995 | WO |
WO 9510319 | Apr 1995 | WO |
WO 9510321 | Apr 1995 | WO |
WO 9510978 | Apr 1995 | WO |
WO 9515115 | Jun 1995 | WO |
WO 9517222 | Jun 1995 | WO |
WO 9530380 | Nov 1995 | WO |
WO 9610961 | Apr 1996 | WO |
WO 9626675 | Sep 1996 | WO |
WO 9639966 | Dec 1996 | WO |
WO 9706727 | Feb 1997 | WO |
WO 9717904 | May 1997 | WO |
WO 9718853 | May 1997 | WO |
WO 9725916 | Jul 1997 | WO |
WO 9725918 | Jul 1997 | WO |
WO 9725919 | Jul 1997 | WO |
WO-9729699 | Aug 1997 | WO |
WO 9732525 | Sep 1997 | WO |
WO 9733526 | Sep 1997 | WO |
WO 9737607 | Oct 1997 | WO |
WO-9738748 | Oct 1997 | WO |
WO 9741793 | Nov 1997 | WO |
WO 9743970 | Nov 1997 | WO |
WO 9745156 | Dec 1997 | WO |
WO 9817187 | Apr 1998 | WO |
WO 9824488 | Jun 1998 | WO |
WO 9826724 | Jun 1998 | WO |
WO 9837822 | Sep 1998 | WO |
WO 9848881 | Nov 1998 | WO |
WO 9849957 | Nov 1998 | WO |
WO 9902096 | Jan 1999 | WO |
WO-9902096 | Jan 1999 | WO |
WO 9904696 | Feb 1999 | WO |
WO 9948421 | Sep 1999 | WO |
WO 9949788 | Oct 1999 | WO |
WO 9956812 | Nov 1999 | WO |
WO 9959486 | Nov 1999 | WO |
WO 0045706 | Aug 2000 | WO |
WO 0057495 | Sep 2000 | WO |
WO 0103594 | Jan 2001 | WO |
WO 0105305 | Jan 2001 | WO |
WO-0105306 | Jan 2001 | WO |
WO 0128623 | Apr 2001 | WO |
WO 0145550 | Jun 2001 | WO |
WO 0166189 | Sep 2001 | WO |
WO 0170112 | Sep 2001 | WO |
WO 0172234 | Oct 2001 | WO |
WO 0172373 | Oct 2001 | WO |
WO-0180708 | Nov 2001 | WO |
WO 0182778 | Nov 2001 | WO |
WO 0205720 | Jan 2002 | WO |
WO 0205722 | Jan 2002 | WO |
WO 0205868 | Jan 2002 | WO |
WO 0230310 | Jan 2002 | WO |
WO 0209610 | Feb 2002 | WO |
WO 0221995 | Mar 2002 | WO |
WO 0224050 | Mar 2002 | WO |
WO 0226142 | Apr 2002 | WO |
WO 0240093 | May 2002 | WO |
WO 0245608 | Jun 2002 | WO |
WO 02077774 | Oct 2002 | WO |
WO-02102231 | Dec 2002 | WO |
Entry |
---|
AFx, inc., “FLEX Surgical Ablation Device: Instructions for Use,” Document No. 900044 Rev A; Mar. 28, 2000: 1-9. |
AFx, inc., “AFx Microwave Generator, Series 1000; User's Manual,” Document No. 900067/A/1310, (2000): 1-13. |
AFx, inc., “FLEX10™: Accessory for the Afx Microwave Ablation Aystem; Instructions for Use,” Document No. 900077/C/1638, (2001): 1-8. Supplemental Document No. 900106/A/1586. |
Boston Scientific, EP Technologies, “Cobra® Electrosurgical Unit, Operator's Manual: 4810 & 4811,” Document No. 11292-001 EAW Ver AC, Feb. 2000; pp. 1-1 thru 9-2. |
Boston Scientific, EP Technologies, “Cobra® Surgical Probe; Directions for Use,” Document No. 13954-001 Rev A, Oct. 2001: p. 3. |
Boston Scientific, EP Technologies, “Cobra® RF System: The first surgical system for creating linear lesions.” Document No. DEP-225 Rev A, Jan. 2002. |
Caccitolo et al., “Open-Heart Endocardial Radiofrequency Ablation: . . . ” J of Surgical Research, (2001); 97: 27-33. |
Chevalier, et al., “Thoracoscopic Epicardial Radiofrequency Ablation for Vagal Atrial Fibrillation in Dogs,” PACE Jun. 1999; 22 (Part I), 880-886. |
Cox et al., “The Surgical Treatment of Atrial Fibrillation, IV Surgical Technique,” J Thorac Cardiovasc Surg, 1991; 101: 584-592. |
Demazumder et al., “Comparison of Irrigated Electrode Designs for Radiofrequency Ablation of Myocardium,” J of Interventional Cardiac Electrophysiology5, (2001): 391-400. |
Elvan et al., “Radiofrequency Catheter Ablation of the Atria Eliminates Pacing-Induced Sustained Atrial Fibrillation and Reduces Connexin in 43 Dogs,” Circulation, 1997;96(5):1675-1685. |
Fieguth et al., “Inhibition of Atrial Fibrillation by Pulmonary Vein Isolation and Auricular Resection—Experimental Study in a Sheep Model,” European Journal of Cardio-Thoracic Surgery, 1997;11:714-721. |
He et al., “Preliminary Results Using Ultrasound Energy for Ablation of the Ventricular Myocardium in Dogs,” Am J Card, 1994;73:1029-1031. |
He et al., “Application of Ultrasound Energy for Intracardiac Ablation of Arrhythmias,” The European Society of Cardiology, 1995;16:961-966. |
Hunt, John W., “Application of Microwave, Ultrasound and Radiofrequency Heating,” Natl Cancer Inst Monogr, (1982); 61: 447-456. |
Hynynen et al., “Cylindrical Ultrasonic Transducers for Cardiac Catheter Ablation,” IEEE Transactions on Biomedical Engineering, 1997;44(2):144-151. |
Inoue et al., “Video Assisted Thoracoscopic and Cardioscopic Radiofrequency Maze Ablation,” ASAIO Journal, 1997;43:334-337. |
Jumrussirikul et al., “Prospective Comparison of Temperature Guided Microwave and Radiofrequency Catheter Ablation in the Swine Heart,” PACE (1998); 21: 1364-1374. |
Lee, et al., “High Intensity Focused Ultrasound Effect on Cardiac Tissues: Potential for Clinical Application,” Echocardiography, (2000) vol. 17, No. 6, Part 1: 563-566. |
Liem et al. “Microwave Catheter Ablation Using a Clinical Prototype System with a Lateral Firing Antenna Design,” PACE, (1998); 21 [pt 1]: 714-721. |
McRury, Ian D., Haines, David E., “Ablation for the Treatment of Arrhythmais,” Proceedings of the IEEE, (1996); vol. 84, No. 3: 404-415. |
Mitchell et al., “Morphological and Physiological Characterictics of Discontinuous Linear Atrial Ablations During Atrial Pacing and Atrial Fibrillation,” J Cardiovas Electroohysiol, (1999); vol. 10: 378-386. |
Mittleman et al., “Use of the Saline Electrode Catheter for Improved Energy Delivery and Increased Lesion Size in Radiofrequency Catherter Ablation,” PACE, (1995); 18[Pt 1]: 1022-1027. |
Ohkubo et al., “Experimental Study of Catheter Ablation Using Ultrasound Energy in Canine and Porcine Hearts,” Jpn Heart J, (1998); 39: 399-409. |
Olgin et al., “Electrophysical Effects of Long. Linear Atrial Lesions Placed Under Intracardiac Ultrasound Guidance,” Circulation, 1997;96(8):2715-2721. |
Petersen et al., “Tissue Temperatures and Lesion Size During Irrigated Tip Catheter Radiofrequency Ablation: . . . ,” PACE, (2000); 23: 8-17. |
Pfeiffer et al., “Epicardial Neodymium . . . ,” Am Heart J, 1996:94(12):3221-3225. |
Righetti et al., “Elastographic Characterization of HIFU-Induced Lesions in Canine Livers,” Ultrasound in Med. & Biol., (1999), vol. 25 No. 7; 1099-1113. |
Sibille et al., “Characterization of Extracorporeal Ablation of Normal and Tumor-Bearing Liver Tissue by High Intensity Focused Ultrasound,” Ultrasound in Med. & Biol., (1993); vol. 19, No. 9: 803-813. |
Sosa et al., “Radiofrequency Catheter Ablation of Ventricular Tachycardia Guided by Nonsurgical Epicardial Mapping in Chronic Chagasic heart Disease,” PACE, Jan. 1999; 22 (Part I), 128-130. |
Strickberger et al., “Extracardiac Ablation of the Canine Atrioventricular Junction by Use of High-Intensity Focused Ultrasound,” Circulation, (1999); 100: 203-208. |
Thomas et al., “Microwave Ablation of Myocardial Tissue: . . . ” J Cardiovasc Electrophysiol, (1999); vol. 10: 72-78. |
Vanderbrink et al., “Safety and Efficacy of a Steerable Temperature Monitoring Microwave Catheter System for Ventriculat Myocardial Ablation,” J Cardiovasc Electrophysiol, (2000); vol. 11: 305-310. |
Von Oppell et al., “Effectiveness of two radiofrequency ablation systems in atrial tissue,” Euro J of Cardio-thoracic Surg, (2001); 20: 956-960. |
Watanabe et al., “Experimental Application of Microwave Tissue Coagulation to Ventricular Myocardium,” Ann Thorac Surg, (1999); 67: 666-671. |
Weber, “Laser versus Radiofrequency Catheter Ablation of Ventricular Myocardium in Dogs: A Comparative Test,” Cardiology, 1997: 88:346-352. |
Whayne et al., “Microwave Catheter Ablation of Myocardium In Vitro . . . ” Circulation (1994); 89: 2390-2395. |
Williams et al., “Surgical Treatment of Atrial Fibrillation Using Radiofrequency Energy,” Ann Thorac Surg, (2001); 71: 1939-1944. |
Wonnell et al., “Evaluation of Microwave and Radio Frequency Catheter Ablation in a Myocardium-Equivalent Phantom Model,” IEEE Transactions on Biomedical Engineering, 1992;39(10):1086-1095. |
Zimmer et al., “The Feasibility of Using Ultrasound for Cardiac Ablation,” IEEE Transactions on Biomedical Engineering, 1995;42(9):891-897. |
Avitall et al., “A Thoracoscopic Approach to Ablate Atrial Fibrillation Via Linear Radiofrequency Lesion Generation on the Epicardium of Both Atria,” PACE, Apr. 1996;19(Part II):626,#241. |
Jais et al., “Catheter Ablation for Paroxysmal Atrial Fibrillation: High Success Rates with Ablation in the Left Atrium,” Circulation (Nov. 1996) 94:1-675,#3946. |
Lee et al., “Minimally Invasive Epicardial Atrial Linear Ablation Using Cooled Radiofrequency Energy,” Circulation (Nov. 1997) 96:577,I-576,#3221. |
Lindsay et al., “Intraoperative Observations and Epicardial Mapping after Attempted Catheter Ablation of Atrial Fibrillation,” Circulation (Nov. 1997) 96:450,#2517. |
Nakagawa et al, “Use of Atrial Potential Attenuation to Identify Endpoint of Radiofrequency Application for Continuous, Transmural Linear Atrial Ablation,” Circulation (Nov. 1997) 96:577,I-451,#2523. |
Sharma et al., “A Comparison of Sequential with Simultaneous Delivery of RF Energy Application at Multiple Electrodes to Produce Linear Continuous Lesions,” Circulation (Nov. 1997) 96:576,I-576,#3220. |
Sie et al., “Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Valve Surgery,” Circulation (Nov. 1997) 84:I450,#2519. |
Sie et al., “Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery. First Experience,” Circulation (Nov. 1996) 96:450,I-675,#3946. |
Cox, James L. et al., “The surgical treatment of atrial fibrillation”, I. Summary of the current concepts of the mechanism of atrial flutter and atrial fibrillation; J. Thorac Cardiovasc Surgery, vol. 101 1991 , 402-405. |
Cox, James L. et al., “The surgical treatment of atrial fibrillation”, J Thorac Cardiovasc Surgery, vol. 101 1991 , 406-426. |
Cox, James L. et al., “The surgical treatment of atrial fibrillation”, The Journal of Thoracic and Cardiovascular Surgery, vol. 101 Apr. 1991 , 569-583. |
Cox, James L. , “The surgical treatment of atrial fibrillation”, J Thorac Cardiovasc Surgery, vol. 101 1991 , 584-682. |
Number | Date | Country | |
---|---|---|---|
20060004352 A1 | Jan 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10232963 | Aug 2002 | US |
Child | 11129056 | US | |
Parent | 09440823 | Nov 1999 | US |
Child | 10232963 | US | |
Parent | 09356476 | Jul 1999 | US |
Child | 09440823 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09157824 | Sep 1998 | US |
Child | 09356476 | US | |
Parent | 08943683 | Oct 1997 | US |
Child | 09157824 | US | |
Parent | 08735036 | Oct 1996 | US |
Child | 08943683 | US |